Abstract: A detection method of polyethylene glycol monomethyl ether residue in medicinal materials is provided, which belongs to a technical field of medicinal chemical component detection, and includes: detecting a residual amount of mPEG-2000 in 3000-3400 small-molecule mPEG-b-PDLLA by high-performance liquid chromatography with an evaporative light scattering detector. The present invention solves a problem that the copolymer polyethylene glycol monomethyl ether mPEG and the product polyethylene glycol monomethyl ether-polylactic acid block copolymer mPEG-b-PDLLA are difficult to be separated in the high-performance liquid chromatography and there is no UV absorption. The present invention also has high resolution, high sensitivity, sufficient reproducibility and sufficient selectivity.

Abstract: Nitrogenous tricyclic compounds and uses thereof in medicine, in particular, a novel nitrogenous tricyclic compound used as an FXR active regulator and a stereoisomer, a geometrical isomer, a tautomer, a N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and use of the compound in the manufacture of a drug for treating a disease and/or disorder regulated by FXR. A pharmaceutically acceptable composition containing the compound and a method of treating a disease and/or disorder mediated by FXR comprising administering the compound or pharmaceutical composition thereof.

Abstract: Nitrogenous tricyclic compounds and uses thereof in medicine, in particular, a novel nitrogenous tricyclic compound used as an FXR active regulator and a stereoisomer, a geometrical isomer, a tautomer, a N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and use of the compound in the manufacture of a drug for treating a disease and/or disorder regulated by FXR. A pharmaceutically acceptable composition containing the compound and a method of treating a disease and/or disorder mediated by FXR comprising administering the compound or pharmaceutical composition thereof.

Abstract: A detection method of polyethylene glycol monomethyl ether residue in medicinal materials is provided, which belongs to a technical field of medicinal chemical component detection, and includes: detecting a residual amount of mPEG-2000 in 3000-3400 small-molecule mPEG-b-PDLLA by high-performance liquid chromatography with an evaporative light scattering detector. The present invention solves a problem that the copolymer polyethylene glycol monomethyl ether mPEG and the product polyethylene glycol monomethyl ether-polylactic acid block copolymer mPEG-b-PDLLA are difficult to be separated in the high-performance liquid chromatography and there is no UV absorption. The present invention also has high resolution, high sensitivity, sufficient reproducibility and sufficient selectivity.

Abstract: A nitrogen-containing tricyclic compound which acts as modulator of FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the use of the compound for the treatment of disease and/or condition mediated by FXR are described. And a pharmaceutical composition containing the compound disclosed herein and a method of treatment of disease and/or condition mediated by FXR comprising administering the compound or the pharmaceutical composition thereof are also described.

Abstract: A nitrogen-containing tricyclic compound which acts as modulator of FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the use of the compound for the treatment of disease and/or condition mediated by FXR are described. And a pharmaceutical composition containing the compound disclosed herein and a method of treatment of disease and/or condition mediated by FXR comprising administering the compound or the pharmaceutical composition thereof are also described.

Abstract: The present invention relates to novel tricyclic compounds which can bind to FXR and act as modulators of the FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the uses of the compounds for the treatment of diseases and/or conditions mediated by FXR. The invention further provides a pharmaceutical composition containing the compound disclosed herein and a method of treatment of diseases and/or conditions mediated by FXR comprising administering the compound or the pharmaceutical composition.

Abstract: The present invention relates to novel tricyclic compounds which can bind to FXR and act as modulators of the FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the uses of the compounds for the treatment of diseases and/or conditions mediated by FXR. The invention further provides a pharmaceutical composition containing the compound disclosed herein and a method of treatment of diseases and/or conditions mediated by FXR comprising administering the compound or the pharmaceutical composition.

Abstract: A method of modeling includes quantifying a co-operative strength value for a plurality of pairs of variables, and identifying a clique of at least three variables based on a graph of the co-operative strength values of a plurality of pairs of variables. The method also includes selecting a first pair of variables of the plurality of pairs of variables having a high co-operative strength value. A second clique may also be identified. A model of the first clique and a model of the second clique are made. The outputs of these models are combined to form a combined model which is used to make various decisions with respect to real time data.

Abstract: A method of modeling includes quantifying a co-operative strength value for a plurality of pairs of variables, and identifying a clique of at least three variables based on a graph of the co-operative strength values of a plurality of pairs of variables. The method also includes selecting a first pair of variables of the plurality of pairs of variables having a high co-operative strength value. A second clique may also be identified. A model of the first clique and a model of the second clique are made. The outputs of these models are combined to form a combined model which is used to make various decisions with respect to real time data.